Treatment Regimens and Response Rates in Early TNBC: A Review of Real‐World Practice in the Second Decade of the 21st Century

Key Points

• This review aims to analyze treatment regimens and response rates in early triple-negative breast cancer (TNBC) based on real-world practices.
• Reviewed clinical trial evidence
• Analyzed implementation of treatments
• Examined early TNBC patient outcomes
• Higher rates of pathologic complete response (pCR) observed in clinical practice
• Successful incorporation of clinical trial findings into real-world treatments
• Future focus will be on immune checkpoint inhibitors in treatment approaches

Abstract